Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in CLL and MCL Patients Undergoing Allogeneic Stem Cell Transplantation
2018-003465-33Phase 2Terminated
- Sponsor
- Polish Lymphoma Research Group
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Polish Lymphoma Research Group. Primary endpoints: overall response rate, complete response rate and 1 more. Started Jan 2019; status: terminated.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2018-003465-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003465-33.